Inclusion Criteria:

1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria:

* New initiated (within 4 weeks of registry entry) on HUMIRA® therapy;
* Initiated HUMIRA® therapy in the past and:

* Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy.

OR
* Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of AbbVie sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug).
2. Patient is willing to consent to data being collected and provided to AbbVie;
3. Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry.

Exclusion Criteria:

- Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.